Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Primary Myelofibrosis: Risk Stratification By Ipss Identifies Patients With Poor Clinical Outcome.
Author: Benites, Bruno Deltreggia
Lima, Carolina Silva Costa
Lorand-Metze, Irene
Delamain, Marcia Torresan
Oliveira, Gislaine Borba
Almeida, Daiane de
Souza, Carmino Antonio de
Vassallo, Jose
Pagnano, Katia Borgia Barbosa
Abstract: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with overall survival. A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and high, 5 (7%); and IPSS- low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%). Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly shorter overall survival relative to the low risk groups (intermediate-1 and low) (p = 0.02). These results emphasize the importance of the IPSS prognostic score for risk assessment in predicting the clinical outcome of primary myelofibrosis patients.
Subject: Adult
Aged, 80 And Over
Janus Kinase 2
Middle Aged
Predictive Value Of Tests
Primary Myelofibrosis
Reproducibility Of Results
Risk Assessment
Risk Factors
Severity Of Illness Index
Treatment Failure
Citation: Clinics (são Paulo, Brazil). v. 68, n. 3, p. 339-43, 2013.
Rights: aberto
Date Issue: 2013
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_23644853.pdf184.33 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.